Halozyme Just Bought Its Next Decade Of Growth

Halozyme acquires Elektrofi to expand drug delivery with high-concentration biologics. Discover how this boosts growth and ...
The Malaysian Reserve

Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...
The Healthy @Reader's Digest on MSN

My Doctor Heard Something Strange in My Voice—Then Diagnosed Me with This Autoimmune Disease

This rare autoimmune disease affects tens of thousands of Americans. A Texas farmer shares his journey to addressing it.
Le Lézard

LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference

LEO Pharma A/S, a global leader in medical dermatology, is advancing the understanding of skin disease and its impact on patients' lives with the presentation of 46 abstracts at the upcoming 2025 Fall ...